Viking Therapeutics announces pricing of public offering of common stock
11/04/2016
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders, announced the pricing of an underwritten public offering of 7,500,000 shares of its common stock and warrants to purchase up to 7,500,000 shares of its common stock at a public offering price of USD 1.25 per share of common stock and related warrant, for total expected gross proceeds to Viking of approximately USD 9,375,000, before deducting underwriting discounts, commissions, and other offering expenses.
The warrants have an exercise price of USD 1.50 per share of common stock, are exercisable immediately and will expire five years from the date of issuance. Additionally, Viking has granted the underwriters a 45-day option to purchase up to an additional 1,125,000 shares of its common stock and/or warrants to purchase up to an additional 1,125,000 shares of its common stock to cover over-allotments, if any. All of the shares of common stock and warrants are being offered by Viking.
The shares of common stock are currently listed on the Nasdaq Capital Market under the ticker symbol "VKTX". The warrants are expected to begin trading on the Nasdaq Capital Market on April 8, 2016 under the ticker symbol "VKTXW". The offering is expected to close on or about April 13, 2016, subject to the satisfaction of customary closing conditions.
Maxim Group LLC is acting as the sole book-running manager for the offering, while FBR Capital Markets & Co. is acting as the lead manager.
11/04/2016
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders, announced the pricing of an underwritten public offering of 7,500,000 shares of its common stock and warrants to purchase up to 7,500,000 shares of its common stock at a public offering price of USD 1.25 per share of common stock and related warrant, for total expected gross proceeds to Viking of approximately USD 9,375,000, before deducting underwriting discounts, commissions, and other offering expenses.
The warrants have an exercise price of USD 1.50 per share of common stock, are exercisable immediately and will expire five years from the date of issuance. Additionally, Viking has granted the underwriters a 45-day option to purchase up to an additional 1,125,000 shares of its common stock and/or warrants to purchase up to an additional 1,125,000 shares of its common stock to cover over-allotments, if any. All of the shares of common stock and warrants are being offered by Viking.
The shares of common stock are currently listed on the Nasdaq Capital Market under the ticker symbol "VKTX". The warrants are expected to begin trading on the Nasdaq Capital Market on April 8, 2016 under the ticker symbol "VKTXW". The offering is expected to close on or about April 13, 2016, subject to the satisfaction of customary closing conditions.
Maxim Group LLC is acting as the sole book-running manager for the offering, while FBR Capital Markets & Co. is acting as the lead manager.
